RIO DE JANEIRO, BRAZIL - The Brazilian Health Regulatory Agency (Anvisa), on Thursday, April 8, authorized Phase 3 trials in Brazil of one more vaccine against Covid-19. The immunizer is being developed by the biopharmaceutical Medicago R&D Inc. from Canada and the British pharmaceutical giant GlaxoSmithKline (GSK).
The clinical trials to be conducted in Brazil are last stage Phase 3 and will involve 3,500 volunteers over the age of 18.
Participants will receive a single dose of the vaccine or a placebo (inactive substance), to serve as a control group. The determination of who receives the vaccine . . .